Evidence map›Paper›PMID 40261013›Full record

ArticleJournal of virology2025

Deciphering lentiviral Vpr/Vpx determinants required for HUSH and SAMHD1 antagonism highlights the molecular plasticity of these evolutionary conflicts.

Pauline Larrous, Cassandre Garnier, Marina Morel, Michael M Martin, Karima Zarrouk, Sarah Maesen, Roy Matkovic, Andrea Cimarelli, Lucie Etienne, Florence Margottin-Goguet

Abstract read
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Pauline LarrousInstitut Cochin, Université Paris Cité, INSERM U1016, CNRS UMR8104, Paris, France.
Cassandre GarnierInstitut Cochin, Université Paris Cité, INSERM U1016, CNRS UMR8104, Paris, France.
Marina MorelInstitut Cochin, Université Paris Cité, INSERM U1016, CNRS UMR8104, Paris, France.
Michael M MartinInstitut Cochin, Université Paris Cité, INSERM U1016, CNRS UMR8104, Paris, France.
Karima ZarroukInstitut Cochin, Université Paris Cité, INSERM U1016, CNRS UMR8104, Paris, France.
Sarah MaesenCIRI, Centre International de Recherche en Infectiologie, Inserm U1111, Université Claude Bernard Lyon 1, CNRS UMR5308, Ecole Normale Supérieure de Lyon, Univ Lyon, Lyon, France.
Roy MatkovicInstitut Cochin, Université Paris Cité, INSERM U1016, CNRS UMR8104, Paris, France.ORCID 0000-0002-0289-324X
Andrea CimarelliCIRI, Centre International de Recherche en Infectiologie, Inserm U1111, Université Claude Bernard Lyon 1, CNRS UMR5308, Ecole Normale Supérieure de Lyon, Univ Lyon, Lyon, France.ORCID 0000-0003-0892-0488
Lucie EtienneCIRI, Centre International de Recherche en Infectiologie, Inserm U1111, Université Claude Bernard Lyon 1, CNRS UMR5308, Ecole Normale Supérieure de Lyon, Univ Lyon, Lyon, France.ORCID 0000-0002-8585-7534
Florence Margottin-GoguetInstitut Cochin, Université Paris Cité, INSERM U1016, CNRS UMR8104, Paris, France.ORCID 0000-0002-3124-6690

Funding

Agence Nationale de Recherches sur le Sida et les Hépatites Virales #ECTZ118944Agence Nationale de Recherches sur le Sida et les Hépatites Virales #ECTZ173023Fondation pour la Recherche Médicale EQU202203014684 to FMGSidaction 21-1-AEQ-12972-2
6 · The paper itself

Abstract

SAMHD1 and the HUSH complex constitute two blocks during primate lentivirus infection, the first by limiting reverse transcription and the second by inhibiting proviral expression. Vpr and Vpx of specific lentiviral lineages have evolved to antagonize these antiviral proteins. While the antagonism of SAMHD1 has been well characterized, the evolutionary and molecular determinants of the antagonism against HUSH are unknown. We used chimeric Vpr proteins between SIVagm.Ver and SIVagm.Gri lentiviruses infecting two African green monkey species to investigate viral determinants involved in HUSH and SAMHD1 antagonisms. We found that different interfaces of closely related Vpr proteins are engaged to degrade different SAMHD1 haplotypes. In addition, we identified distinct viral determinants in SIVagm.Ver Vpr for SAMHD1 and HUSH degradation. The substitution of one residue in SIVagm.Gri Vpr is sufficient to gain the capacity to degrade SAMHD1, while the substitution of α-helix 3 confers HUSH antagonism. We also found that Vpx proteins of HIV-2 from people living with HIV have different abilities to degrade HUSH. These phenotypes rely on small changes in either the N or C terminal part of Vpx, depending on the context. On the host side, we found that HIV-2 and SIVsmm Vpx degrading HUSH from human and vervet monkey cells cannot degrade HUSH in owl monkey cells, suggesting some host species specificity. Altogether, we highlight the molecular plasticity and constraints of viral proteins to adapt to host restrictions. HUSH, like SAMHD1, may have been engaged in ancient and more recent coevolution conflicts with lentiviruses and a player in viral fitness.IMPORTANCEAntiviral host proteins, the so-called restriction factors, block lentiviruses at different steps of their viral replication cycle. In return, primate lentiviruses may counteract these immune proteins to efficiently spread

Indexed as

Gene Products, vprSAM Domain and HD Domain-Containing Protein 1Simian Immunodeficiency VirusViral Regulatory and Accessory ProteinsAnimalsChlorocebus aethiopsEvolution, MolecularHEK293 CellsHIV-2HumansGene Products, vprSAM Domain and HD Domain-Containing Protein 1SAMHD1 protein, humanViral Regulatory and Accessory ProteinsVPX protein, Human immunodeficiency virus 2VPX protein, Simian immunodeficiency viruscoevolutionHIVHUSHrestriction factorsSAMHD1SIVviral antagonism

Identifiers

PMID40261013
PMCPMC12090772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.